$Regeneron Pharmaceuticals (REGN.US)$
Can Dupixent Transform Rare Skin Disease Treatment? New Trial Data Reveals Breakthrough

$Regeneron Pharmaceuticals (REGN.US)$ higher low?

$Regeneron Pharmaceuticals (REGN.US)$
Regeneron's Multiple Myeloma Drug Clears Critical EU Regulatory Hurdle - What's Next?

$Regeneron Pharmaceuticals (REGN.US)$
Can Regeneron's Cancer Drug With 80% Response Rate Secure FDA Approval For Lymphoma?

$Regeneron Pharmaceuticals (REGN.US)$
Revolutionary Hearing Breakthrough: Can This Gene Therapy End Childhood Genetic Deafness?

$Regeneron Pharmaceuticals (REGN.US)$ In traditional technical analysis, you would think this is likely reversed given the engulfing pattern with strong volume at an earnings event. But in this trending market, a higher high has to be established.

$Esperion Therapeutics (ESPR.US)$ Jan 23, 2025 Three analysts are bullish on Esperion Therapeutics with price targets on this $2 stock ranging from $7 to $16 a share.
Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, Esperion has positioned itself as an acquisition target for larger pharmaceutical compa...

$Regeneron Pharmaceuticals (REGN.US)$ Wow, that was a nice dip buying. I didn’t follow their events closely. I bought back somewhat early on Jan 10.

$Regeneron Pharmaceuticals (REGN.US)$ It’s doing this kind of thing. Kind of scary. Nobody wants it for above 700.